We Need Your Help

In order to keep funding groundbreaking, lifesaving research projects, we require your continued support.


Join Our Newsletter

Get the latest PA events and research developments.
First Name
Last Name
E-mail
Postcode

Corporate Partners

      

The Australian Prostate Cancer Research

Centre Queensland


One of the major groups that the PA Research Foundation raises funds for is The Australian Prostate Cancer Research Centre – Queensland (APCRC – Q).  The APCRC-Q is a collaboration between the Princess Alexandra Hospital and the Queensland University of Technology (QUT). It is a research centre that is dedicated to prostate cancer, and employs a multidisciplinary approach in getting results from ‘the bench to the bedside’.

 
 

The APCRC – Q focuses exclusively on prostate cancer, and is a hub for prostate cancer research in Brisbane.  It is assembled into a multidisciplinary framework that integrates research activities from discovery through to clinical trials. We seek to link to multiple Institutes with advanced technologies in Queensland, in order to encourage and foster applications of their respective expertise to prostate cancer. The APCRC – Q collaborates with major prostate cancer research groups and relevant clinical societies, both in Australia and overseas.

Aims and Objectives

 

The overall aim of the ACPRC – Q is to assemble a large, coordinated multidisciplinary research team able to seamlessly span the discovery, therapeutic and diagnostic development spectrum of prostate cancer.

Research Aims

The ACPRC – Q's vision is to develop new therapuetics and predictive biomarkers, via a collaborative, transdisciplinary, translational approach. We will span discovery science through to clinical evaluation, and will be underpinned by leading edge technology. Our activities will be greatly facilitated by local, national and international collaborations.

Research Objectives

Objectives of the APCRC – Q focus on therapeutic target development, and biomarkers for genetic predisposition, early detection, prognosis, and treatment response indicators. Our objectives will inform and drive improved clinical practice, and are outlined as follows:
  • develop, evaluate, and validate novel biomarkers for prostate cancer detection and patient risk profile stratification
  • accelerate discovery and pre-clinical development of candidate drugs, and commercial development of anti-cancer therapeutics
  • clinically evaluate novel therapeutics as single agent and in combination with existing therapeutic drugs in Phase I, II and III trials within a multidisciplinary prostate uro-oncology clinical trials centre including urologists, medical oncologists, radiation oncologists, and endocrinologists
  • improve management of prostate cancer patients in Australia through implementing the latest approved advances in prostate cancer treatments.
 

PA Research Foundation
Building 1, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba Qld 4102
Phone: 07 3176 2359     Fax: 07 3176 7303
Synergy 8 | Results Web Design